Inhibition of metadherin sensitizes breast cancer cells to AZD6244

Reference

• Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J 2008; 14:428 - 34; http://dx.doi.org/10.1111/j.1524-4741.2008.00618.x; PMID: 18821930
   PubMed Web of Science ®Google Scholar
• Krcova Z, Ehrmann J, Krejci V, Eliopoulos A, Kolar Z. Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152:21 - 5; PMID: 18795070
   PubMed Web of Science ®Google Scholar
• Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591 - 602; http://dx.doi.org/10.1038/nrc1670; PMID: 16056258
   PubMed Web of Science ®Google Scholar
• Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, et al. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res 2009; 69:4484 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-08-3740; PMID: 19366802
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57 - 70; http://dx.doi.org/10.1016/S0092-8674(00)81683-9; PMID: 10647931
   PubMed Web of Science ®Google Scholar
• Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004; 9:361 - 77; http://dx.doi.org/10.1634/theoncologist.9-4-361; PMID: 15266090
   PubMed Web of Science ®Google Scholar
• Gasparini G. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005; 16:iv28 - 36; http://dx.doi.org/10.1093/annonc/mdi905; PMID: 15923426
   PubMed Web of Science ®Google Scholar
• Schlotter CM, Vogt U, Allgayer H, Brandt B. Molecular targeted therapies for breast cancer treatment. Breast Cancer Res 2008; 10:211; http://dx.doi.org/10.1186/bcr2112; PMID: 18671839
   PubMed Web of Science ®Google Scholar
• Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008; 65:3525 - 44; http://dx.doi.org/10.1007/s00018-008-8170-7; PMID: 18668205
   PubMed Web of Science ®Google Scholar
• Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22:153 - 83; http://dx.doi.org/10.1210/er.22.2.153; PMID: 11294822
   PubMed Web of Science ®Google Scholar
• Pagès G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, et al. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000; 902:187 - 200; http://dx.doi.org/10.1111/j.1749-6632.2000.tb06313.x; PMID: 10865838
   PubMed Web of Science ®Google Scholar
• Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 2007; 120:3688 - 99; http://dx.doi.org/10.1242/jcs.010488; PMID: 17895366
   PubMed Web of Science ®Google Scholar
• Price DJ, Avraham S, Feuerstein J, Fu Y, Avraham HK. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3-kinase and ERK 1,2 pathways. Cell Commun Adhes 2002; 9:87 - 102; http://dx.doi.org/10.1080/15419060214147; PMID: 12487410
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis 2010; 15:795 - 804; http://dx.doi.org/10.1007/s10495-010-0483-y; PMID: 20221697
   PubMed Web of Science ®Google Scholar
• Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS ONE 2010; 5:e13026; http://dx.doi.org/10.1371/journal.pone.0013026; PMID: 20885957
   PubMedGoogle Scholar
• Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008; 68:6145 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-08-1430; PMID: 18676837
   PubMed Web of Science ®Google Scholar
• Yoon J, Koo KH, Choi KY. MEK1/2 Inhibitors AS703026 and AZD6244 may be potential therapies for kras mutated colorectal cancer that is resistant to egfr monoclonal antibody therapy. Cancer Res 2011; 71:445 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-10-3058; PMID: 21118963
   PubMed Web of Science ®Google Scholar
• Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ, et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 2010; 49:353 - 62; http://dx.doi.org/10.1002/mc.20607; PMID: 20358631
   PubMed Web of Science ®Google Scholar
• Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010; 9:1985 - 94; http://dx.doi.org/10.1158/1535-7163.MCT-10-0037; PMID: 20587667
   PubMed Web of Science ®Google Scholar
• Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007; 92:4712 - 8; http://dx.doi.org/10.1210/jc.2007-1184; PMID: 17878251
   PubMed Web of Science ®Google Scholar
• Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, et al. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res 2010; 70:4709 - 18; http://dx.doi.org/10.1158/0008-5472.CAN-09-4524; PMID: 20484037
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6:2209 - 19; http://dx.doi.org/10.1158/1535-7163.MCT-07-0231; PMID: 17699718
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26:2139 - 46; http://dx.doi.org/10.1200/JCO.2007.14.4956; PMID: 18390968
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010; 5:1630 - 6; http://dx.doi.org/10.1097/JTO.0b013e3181e8b3a3; PMID: 20802351
   PubMed Web of Science ®Google Scholar
• Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011; 29:1021 - 8; http://dx.doi.org/10.1007/s10637-010-9392-8; PMID: 20127139
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010; 55:668 - 77; http://dx.doi.org/10.1002/pbc.22576; PMID: 20806365
   PubMed Web of Science ®Google Scholar
• Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010; 70:8736 - 47; http://dx.doi.org/10.1158/0008-5472.CAN-10-0902; PMID: 20959481
   PubMed Web of Science ®Google Scholar
• Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 2002; 21:3592 - 602; http://dx.doi.org/10.1038/sj.onc.1205445; PMID: 12032861
   PubMed Web of Science ®Google Scholar
• Li C, Liu J, Lu R, Yu G, Wang X, Zhao Y, et al. AEG -1 Overexpression: A novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers. Int J Gynecol Cancer 2011; 21:602 - 8; http://dx.doi.org/10.1097/IGC.0b013e3182145561; PMID: 21543927
   PubMed Web of Science ®Google Scholar
• Yu C, Chen K, Zheng H, Guo X, Jia W, Li M, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis 2009; 30:894 - 901; http://dx.doi.org/10.1093/carcin/bgp064; PMID: 19304953
   PubMed Web of Science ®Google Scholar
• Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009; 119:465 - 77; http://dx.doi.org/10.1172/JCI36460; PMID: 19221438
   PubMed Web of Science ®Google Scholar
• Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009; 15:9 - 20; http://dx.doi.org/10.1016/j.ccr.2008.11.013; PMID: 19111877
   PubMed Web of Science ®Google Scholar
• Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, et al. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci USA 2009; 106:21300 - 5; http://dx.doi.org/10.1073/pnas.0910936106; PMID: 19940250
   PubMed Web of Science ®Google Scholar
• Song L, Li W, Zhang H, Liao W, Dai T, Yu C, et al. Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. J Pathol 2009; 219:317 - 26; http://dx.doi.org/10.1002/path.2595; PMID: 19644957
   PubMed Web of Science ®Google Scholar
• Li C, Li R, Song H, Wang D, Feng T, Yu X, et al. Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol 2011; 103:184 - 92; http://dx.doi.org/10.1002/jso.21788; PMID: 21259255
   PubMed Web of Science ®Google Scholar
• Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene 2007; 26:7647 - 55; http://dx.doi.org/10.1038/sj.onc.1210572; PMID: 17563745
   PubMed Web of Science ®Google Scholar
• Li J, Yang L, Song L, Xiong H, Wang L, Yan X, et al. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. Oncogene 2009; 28:3188 - 96; http://dx.doi.org/10.1038/onc.2009.171; PMID: 19633686
   PubMed Web of Science ®Google Scholar
• Su P, Zhang Q, Yang Q. Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue. Diagn Pathol 2010; 5:38; http://dx.doi.org/10.1186/1746-1596-5-38; PMID: 20565850
   PubMed Web of Science ®Google Scholar
• Li X, Kong X, Huo Q, Guo H, Yan S, Yuan C, et al. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci 2011; 102:1151 - 7; http://dx.doi.org/10.1111/j.1349-7006.2011.01919.x; PMID: 21371176
   PubMed Web of Science ®Google Scholar
• Khuda II, Koide N, Noman AS, Dagvadorj J, Tumurkhuu G, Naiki Y, et al. Astrocyte elevated gene-1 (AEG-1) is induced by lipopolysaccharide as toll-like receptor 4 (TLR4) ligand and regulates TLR4 signalling. Immunology 2009; 128:e700 - 6; http://dx.doi.org/10.1111/j.1365-2567.2009.03063.x; PMID: 19740331
   PubMedGoogle Scholar
• Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010; 70:2264 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-09-1577; PMID: 20215513
   PubMed Web of Science ®Google Scholar
• Meng J, Peng H, Dai B, Guo W, Wang L, Ji L, et al. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 2009; 8:2073 - 80; http://dx.doi.org/10.4161/cbt.8.21.9844; PMID: 19783898
   PubMed Web of Science ®Google Scholar
• Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010; 5:10; http://dx.doi.org/10.1186/1750-2187-5-10; PMID: 20642839
   PubMedGoogle Scholar
• Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10:138 - 48; http://dx.doi.org/10.1038/ncb1676; PMID: 18204439
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857 - 68; http://dx.doi.org/10.1016/S0092-8674(00)80595-4; PMID: 10102273
   PubMed Web of Science ®Google Scholar
• Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, et al. Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer. Mol Cancer Ther 2010; 9:3351 - 62; http://dx.doi.org/10.1158/1535-7163.MCT-10-0376; PMID: 20923857
   PubMed Web of Science ®Google Scholar
• Liu H, Song X, Liu C, Xie L, Wei L, Sun R. Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells. J Exp Clin Cancer Res 2009; 28:19; http://dx.doi.org/10.1186/1756-9966-28-19; PMID: 19216799
   PubMed Web of Science ®Google Scholar
• Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225 - 37; http://dx.doi.org/10.1016/S0092-8674(04)00302-2; PMID: 15084260
   PubMed Web of Science ®Google Scholar